Hazard ratio for coronary heart disease mortality for SMI patients versus controls (18-49 yrs) Hazard ratio for stroke
|
|
- Rodney Armstrong
- 5 years ago
- Views:
Transcription
1 By Michael Dixon
2 Contents Background to Bipolar Disorder and cardiac risk Mood stabilisers and cardiac risk factors Background to Depression and cardiac risk Antidepressants and cardiac risk factors Any questions?
3 Introduction Hazard ratio for coronary heart disease mortality for SMI patients versus controls (18-49 yrs) 3.22 (95% CI ) (Goodwin :4 ) Hazard ratio for stroke 2.53 (95% CI ) (Goodwin :4 ) For every 30 people who gain 4kg of weight, one will develop hypertension in the next 10 years Approx up to 70% of mental health patients smoke
4 Bipolar V Depression bipolar unipolar Osby U et al. 2001; 58
5 Background to Bipolar Disorder and Cardiac Risk (1) Patients with bipolar 1 may have double the cardiovascular risk of bipolar 2. After suicide and accidents, cardiovascular/all vascular diseases are leading cause of death in bipolar patients 17% have type 2 diabetes and 35% have hypertension (Goodwin :4 )
6 Background to Bipolar Disorder and Cardiac Risk (2) One study of outpatients with bipolar disorder (n=118, mean age 53 years) 84% had hyperlidaemia, 70% had hypertension and 25% had diabetes Clinically significant depressive symptoms raised odds of framingham score > 20%, 6 fold Depressive symptoms were also associated with increased BMI, glucose and BP Slomka JM et al. 2012; 138(3)
7 Fiedorowicz JG et al. 2009: 71.
8 Fiedorowicz JG et al. 2009: 71.
9 Mood stabilisers and cardiac risk (1) Lithium Lithium contra-indicated in cardiac disease Lithium usually benign cardiac side-effects in 20-30% of patients On average starting Lithium can increase QTc by 18.6msecs Weight gain is 2 nd highest reason for non-compliance with lithium (most often in 1 st two years) Significant weight gain (>7%) Odds ratio versus placebo of 1.89 (95% CI , p = 0.002). (McKnight R et al 2012; 379) Weight gain of lithium versus olanzapine odds ratio 0.32 (95% CI , p< , n=285) (McKnight R et al 2012; 379) Lithium versus aripiprazole over 52 weeks +0.74kg against +0.97kg (McIntyre RS et al. 2011; 13(6) )
10 Mood stabilisers and cardiac risk (2) Weight gain - clozapine/olanzapine > quetiapine/risperidone > lithium/valproate (Choong E et al (4) ) Others Carbamazepine can cause a rise in cholesterol, HDL and LDL Valproate and carbamazepine can cause weight gain Topiramate and lamotrigine don t cause weight gain
11 Bowden C et al. 2006: 163(7).
12 Monitoring of patients with Bipolar Disorder Everyone should have: - weight, diet, nutritional status - CVS status inc BP and pulse - Blood glucose and lipids - Liver - U&Es, TFTs and Ca 2+ for people on Li NICE sept 2014
13 Background to Depression and Cardiac Risk Patients with coronary heart disease have 3 times the risk of depression over general population Depressed patients are 2.7 times more likely to die from ischaemic heart disease (Surtees G et al. 2008: 165) Following acute coronary syndrome those who have severe depression have a doubling of their mortality over seven years over those without depression (hazard ratio % CI ) (Glassman A, Bigger Jnr TJ, Gaffney M. 2009;66(9) Diabetes doubles the odds of co-morbid depression
14 Depression and future cardiac disease Swedish twins study, twins Depression and antidepressant use associated with CVD development Risk highest in depressed patients who didn t use antidepressants (HR 1.48, CI ) When the CVD outcomes were split, the association was found with ischaemic stroke but not for coronary heart disease *Rahman I et al. 2013;28(7)
15 Surtees G et al. 2008: 165
16 ENRICHD study Antidepressant drug use was associated with a lower risk for death or nonfatal MI of an adjusted HR of 0.63 (95% CI, ) and decreased risk of dying, with an adjusted HR of 0.63 (95% CI, ).(Writing committee 2003;289) SADHEART sertraline v placebo over 2 years post MI - incidence of severe cardiovascular adverse events was 14.5% with sertraline and 22.4% with placebo (Glassman A et al. 2002;288) 7 year follow up of SADHEART - baseline depression severity (hazard ratio, 2.30; 95% confidence interval, ; P <.006) and failure of depression to improve with either sertraline or placebo (hazard ratio, 2.39; 95% confidence interval, ; P <.001) were strongly and independently associated with longterm mortality (Glassman A et al. 2009;66(9))
17 Stapleberg NJC et al. 2011; 45
18 Cardiac effects of antidepressants Drug Hear t rate BP QTc Arrhythmi a Conduction Tricyclics Increase Postural hypotension prolonged Common in O/D Slows conduction block Na/K channels Trazodone decrease or increase postural hypotension Can prolong Case reports unclear SSRIs (exc citalopram/e scitalopram) Citalopram/ escitalopram Venlafaxine Min/small decrease in HR Small decrease Marginal increase No effect Nil Nil nil Slight drop Depends on dose Doserelated increase Poss increase in O/D Mainly in O/D rare reports in O/D nil Rare reports Mirtazapine Minimal Minimal None None None
19 Antidepressants and risk of cardiovascular disease Scottish Health Survey, adults All cardiovascular events Hazard Ratios (95% CI) Non-medicated 1.00 (reference) TCAs 1.35 ( ) SSRIs 1.11 ( ) Other 0.88 ( ) Any antidepressant 1.19 ( ) *Hamer M et al. 2011; 32
20 Review of QTc prolongation No effect at therapeutic concentrations Mild effect (6-8ms) or only in cases of overdose or intoxication Moderate effect (10-15 ms) Severe effect (>17ms) Duloxetine Citalopram/escit alopram Clomipramine Amitriptyline Mirtazapine Trazodone Fluoxetine Doxepin Sertraline Venlafaxine Imipramine Wenzel-Seifert et al (2011). Nortriptyline
21 Citalopram/escitalopram and QTc Citalopram 20mg = 7.5 msecs 60mg = 16.7 msecs Dose restricted to max 40mg/day (20mg in elderly or hepatic impairment) Escitalopram 10mg = 4.3 msecs 30mg = 10.7 msecs Dose restricted to max 10mg/day in elderly or hepatic impairment Not to be used in patients with prolonged QTc or with other meds that prolong QTc MHRA. 2011; 5(5)
22 Mean (SD) corrected QT (QTc) interval recorded on electrocardiogram days after prescription of antidepressant or methadone, by drug dose Castro V et al. 2013; 346
23
24 Antidepressants and weight gain (1) Weight gain or loss can be part of depression One study showed patients on antidepressant gained 1kg of weight over 12 year period Patten S et al. 2011; 134(1-3) Tricyclic antidepressants increased craving and decreased metabolic rate SSRIs tend to get weight loss initially over first month followed by weight gain in the long term Mirtazapine causes weight gain MAOIs can cause weight gain Least weight gain agomelatine, trazodone or reboxetine, venlafaxine or duloxetine
25 WHI study BMI (kg/m 2 ) Weight (kg) Baseline Year 3 Baseline Year 3 Not depressed Depressed No antidepressant Taking antidepressant Ma Y et al. 2013; 103.
26 Antidepressants and weight gain (2) Serretti A et al. 2010; 71(10).
27 Antidepressants and diabetes (1) 5 year absolute risk for developing diabetes - 1.1% for general population - 1.7% for standard doses of antidepressants ( doses/yr) - 2.3% for higher doses of antidepressants (>400 doses/yr) - OR for diabetes without severe depression 1.93 (95% CI ) and with severe depression OR 2.65 (95% CI ) - Average weight gain 2.5kg (control 1.4kg) (Kivimaki M et al. Antidepressant medication use, weight gain, and risk of type 2 diabetes: a population based study. Diabetes Care 2010; 33:2611-6)
28 Antidepressants and diabetes (2) Kivimaki M et al. 2010; 33.
29 Conclusion When considering the choice of medication for patients consider relevant cardiac risk factors and comorbidities Monitor the physical health side-effects of medication prescribed e.g. Lipids, glucose, weight gain, ECG
30 References (1) Bowden C et al. (2006) Impact of lamotrigine and lithium on weight in obese and non obese patients with bipolar 1 disorder. American Journal of Psychiatry; 163(7): Choong E et al. (2012) Psychotropic drug-induced weight gain and other metabolic complications in a Swiss psychiatric population. Journal of Psychiatric Research 46(4): Castro V et al. (2013) QT interval and antidepressant use: a cross sectional study of electronic health records BMJ 346:f288 doi: /bmj.f288 (Published 29 January 2013) Fiedorowicz JG et al. (2009) Manic/hypomanic symptom burden and cardiovascular mortality in bipolar disorder. Psychosomatic Medicine,71, Glassman A et al. Sertraline Treatment of Major Depression in Patients With Acute MI or Unstable Angina. JAMA. 2002;288(6): Glassman A, Bigger Jnr JT, Gaffney M. (2009) Psychiatric Characteristics Associated With Long-term Mortality Among 361 Patients Having an Acute Coronary Syndrome and Major Depression: Seven-Year Follow-up of SADHART Participants. Archives of General Psychiatry; 2009; 66(9): Goodwin G et al. (2009) Evidence based guidelines for treating bipolar disorder: revised second edition recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology,23(4), Hamer M et al. (2011) Antidepressant medication use and future risk of cardiovascular disease: the Scottish Health Survey. European Heart Journal 32: Hawton K et al. (2010) Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose The British Journal of Psychiatry 196, Kivimaki M et al. (2010) Antidepressant medication use, weight gain, and risk of type 2 diabetes: a population based study. Diabetes Care; 33: Ma Y et al. (2013) Relations of Depressive Symptoms and Antidepressant Use to Body Mass Index and Selected Biomarkers for Diabetes and Cardiovascular Disease. American Journal of Public Health 103:e34 e43. doi: MHRA. (2011) Citalopram and escitalopram: QT interval prolongation new maximum daily dose restrictions (including in elderly patients), contraindications, and warnings. Drug Safety Update 5(5); A1 Mcknight R et al. (2012) Lithium toxicity profile: a systematic review and meta-analysis. Lancet 379; , 25 February. McIntyre RS et al. (2011) A 52-week, double-blind evaluation of the metabolic effects of aripiprazole and lithium in bipolar 1 disorder. The primary care companion to CNS disorders 13(6). NICE. (2006) Bipolar Disorder, Clinical Guidelines 38, July.
31 References (2) Osby U et al. (2001) Excess mortality in bipolar and unipolar disorder in sweden. Archives of General Psychiatry 58: Patten S et al. (2011) Weight gain in relation to major depression and antidepressant medication use. Journal of Affective Disorders; 134(1-3): ) Rahman I et al. (2013) Clinical depression, antidepressant use and risk of future cardiovascular disease. European Journal of Epidemiology 28(7): Slomka JM et al. (2012) Mood disorder symptoms and elevated cardiovascular disease risk in aptients with bipolar disorder. Journal of Affective Disorders; 138(3): , May Serretti A et al. (2010) Antidepressants and body weight: A comprehensive review and meta-analysis. Journal of Clinical Psychiatry; 71(10): Stapleberg NJC et al. (2011) A topographical map of the causal network of mechanisms underlying the relationship between major depressive disorder and coronary heart disease. Australian and New Zealand Journal of Psychiatry; 45: Surtees G et al. (2008) Depression and Ischemic Heart Disease Mortality: Evidence From the EPIC-Norfolk United Kingdom Prospective Cohort Study American Journal of Psychiatry 165 (4) : Taylor D, Paton C, Kapur S. (2012) Prescribing Guidelines in Psychiatry 11 th ed, Chicester: Wiley Blackwell Wenzel-Seifert et al (2011). A review of QTc prolongation. In Bazire S (2014), Psychotropic Drug Directory (pg250), Lloyd-Reinhold Communications. Writing committee for the ENRICHD investigators. Effects of Treating Depression and Low Perceived Social Support on Clinical Events After Myocardial Infarction: The Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA. 2003;289(23):
Volume 4; Number 5 May 2010
Volume 4; Number 5 May 2010 CLINICAL GUIDELINES FOR ANTIDEPRESSANT USE IN PRIMARY AND SECONDARY CARE Lincolnshire Partnership Foundation Trust in conjunction with Lincolnshire PACEF have recently updated
More informationHearts and Minds An ECG Update. Tuesday 18 th November The Met Hotel, Leeds
Hearts and Minds An ECG Update Tuesday 18 th November The Met Hotel, Leeds Ashleigh Bradley Specialist Clinical Pharmacist for Mental Health and Lithium Clinic Airedale NHS Foundation Trust Introduction
More informationPerinatal Mental Health: Prescribing Guidance for Trust Prescribers and GPs
Perinatal Mental Health: Prescribing Guidance for Trust Prescribers and GPs (Version 3 January 2015) Principal Author: Dr Jenny Cooke Consultant Psychiatrist, Brighton & Hove Perinatal Mental Health Service
More informationAntidepressant Treatment of Depression
Antidepressant Treatment of Depression PLEASE REFER TO INTEGRATED CARE PATHWAY FOR INFORMATION RELATING TO THE OVERALL MANAGEMENT OF DEPRESSION SSRI s are first choice agents because they are as effective
More informationSupplementary figures and tables. Figure A: Study schematic
Supplementary figures and tables Figure A: Study schematic Figure B: Percent of patients with a normal (green), borderline (beige), abnormal (brown), or high (red) electrocardiogram 14-90 days after prescription
More informationClinical Guideline / Formulary Document Pharmacy Department Medicines Management Services
Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services DEPRESSION Pharmacological Treatment of Depression NICE guidelines suggest the following stepped care model also
More informationSupplementary Online Content
Supplementary Online Content Renoux C, Vahey S, Dell Aniello S, Boivin J-F. Association of selective serotonin reuptake inhibitors with the risk for spontaneous intracranial hemorrhage. JAMA Neurol. Published
More informationIntroduction to Drug Treatment
Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical
More informationGuidelines on Choice and Selection of Antidepressants for the Management of Depression
Guidelines on Choice and Selection of Antidepressants for the Management of Depression 1. Introduction This guidance should be considered as part of a stepped care approach in the management of depressive
More informationPharmacotherapy of depression
Pharmacotherapy of depression Stuff you already know Stuff you probably know Stuff you possibly don t know Stuff you thought you knew but are mistaken about How long does it take for antidepressants
More informationMood Disorders.
Mood Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationMedications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation
Medications for Anxiety & Behavior in Williams Syndrome Christopher J. McDougle, M.D. Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral
More information4.3 Antidepressants (ADDs) BNF Section 4.3
4.3 Antidepressants (ADDs) BNF Section 4.3 The aim of this guidance is to provide prescribing guidance and highlight good practice. It is not intended to be a comprehensive practice treatment guideline.
More informationPregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition)
Pregnancy General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) In all women of child bearing potential Always discuss the possibility of pregnancy; half of all pregnancies are unplanned
More informationGuidelines on Choice and Selection of Antidepressants for the Management of Depression
Working in partnership: Hertfordshire Partnership University NHS Foundation Trust East and North Hertfordshire Clinical Commissioning Group Herts Valleys Clinical Commissioning Group Guidelines on Choice
More informationPsychiatry in Primary Care: What is the Role of Pharmacist?
Psychiatry in Primary Care: What is the Role of Pharmacist? Benjamin Chavez, PharmD, BCPP, BCACP Clinical Associate Professor Director of Behavioral Health Pharmacy Services January 12, 2019 Disclosure
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Neuropathic pain pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist
More informationIs Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A
Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Faculty/Presenter Disclosures Faculty: Mike Allan Salary: College
More informationMedication management of anxiety & depression. Dr Katie Simpson GP Mental health lead East Berks CCG
Medication management of anxiety & depression Dr Katie impson GP Mental health lead East Berks CCG NICE guidelines for Anxiety tepped Care RIs and NRIs in Anxiety disorders RI ertraline Citalopram Fluoxetine
More informationDiagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD
Diagnosis & Management of Major Depression: A Review of What s Old and New Cerrone Cohen, MD Why You re Treating So Much Mental Health 59% of Psychiatrists Are Over the Age of 55 AAMC 2014 Physician specialty
More informationWhat are you trying to achieve? Falls Prevention, Assessment and Management Strategies. Falls can be classified into four main groups:
What are you trying to achieve? Falls Prevention, Assessment and Management Strategies Dr Adam Darowski Community: Falls risk assessment: Falls risk is 50% per year in 80yr population and higher in those
More informationAntidepressant use and risk of cardiovascular outcomes in people aged 20 to 64: cohort study using primary care database
open access Antidepressant use and risk of cardiovascular outcomes in people aged 20 to 64: cohort study using primary care database Carol Coupland, 1 Trevor Hill, 1 Richard Morriss, 2 Michael Moore, 3
More informationIs Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A
Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Faculty/Presenter Disclosures Faculty: Mike Allan Salary: College
More informationBorderline personality disorder: what role for medication?
Borderline personality disorder: what role for medication? Mike Crawford Imperial College London CNWL NHS Foundation Trust m.crawford@imperial.ac.uk Licensed medication for PD Jane, 34, moderately severe
More informationAnti-Depressant Medications
Anti-Depressant Medications A Introduction: This topic may be a little bit underestimated here in Jordan, while in western countries it has more significance. The function of anti-depressants is to change
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationPresenter Disclosure. Objectives 6/5/2017. Depression, Anxiety, PTSD: A Focus on Pharmacotherapy
Depression, Anxiety, PTSD: A Focus on Pharmacotherapy Robert L Page II, Pharm.D., MSPH, FHFSA, FCCP, FAHA Professor of Clinical Pharmacy Clinical Specialist, Division of Cardiology University of Colorado
More informationPsychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI
Regional Affective Disorders Service Psychopharmacology Northumberland, Tyne and Wear NHS Trust Hamish McAllister-Williams Reader in Clinical Psychopharmacology Department of Psychiatry, RVI Intro NOT
More informationAntidepressant use and risk of suicide and attempted suicide or self harm in people aged 20 to 64: cohort study using a primary care database
open access Antidepressant use and risk of suicide and attempted suicide or self harm in people aged 20 to 64: cohort study using a primary care database Carol Coupland, 1 Trevor Hill, 1 Richard Morriss,
More informationPerinatal Mental Health: Prescribing Guidance for Trust Prescribers and GPs
Perinatal Mental Health: Prescribing Guidance for Trust Prescribers and GPs (Version 3 January 2018) Principal Authors: Dr Jenny Cooke Consultant Psychiatrist, Brighton & Hove Perinatal Mental Health Service
More informationFormulary and Prescribing Guidelines
Formulary and Prescribing Guidelines SECTION 3: TREATMENT OF BIPOLAR AFFECTIVE DISORDER This section provides information regarding the pharmacological management of Bipolar affective disorder in secondary
More informationAntidepressant Selection in Primary Care
Antidepressant Selection in Primary Care R E B E C C A D. L E W I S, D O O O A S U M M E R C M E B R A N S O N, M O 1 5 A U G U S T 2 0 1 5 Objectives Understand the epidemiology of depression. Recognize
More informationA Basic Approach to Mood and Anxiety Disorders in the Elderly
A Basic Approach to Mood and Anxiety Disorders in the Elderly November 1 2013 Sarah Colman MD FRCPC Clinical Fellow, Geriatric Psychiatry Mount Sinai Hospital, University of Toronto Disclosure No conflict
More informationCommon Antidepressant Medications for Adults
(and Citalopram (Celexa) Escitalopram (Lexapro) Fluoxetine (Prozac) Fluoxetine Weekly (Prozac Weekly) 20 in AM w/ food (10 mg in elderly or those w/ panic disorder) 20 40 40 (If age >60yo, max 20) 10 10
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationThe Pharmacological Management of Bipolar Disorder: An Update
Psychobiology Research Group The Pharmacological Management of Bipolar Disorder: An Update R. Hamish McAllister-Williams, MD, PhD, FRCPsych Reader in Clinical Psychopharmacology Newcastle University Hon.
More informationShould we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Primary prevention of CVD Potential output:
More informationGuidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) Guidelines CH Lim, B Baizury, on behalf of Development Group Clinical Practice Guidelines Management of Major Depressive Disorder A. Introduction Major depressive
More informationPart of GP Annual Health Check?
Table A.1 Overview of physical health monitoring in Severe Mental Illness (SMI). isk factor to be monitored at least annually Part of GP Annual Health Check? Needs intervention? History/lifestyle Family
More informationAppendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over)
Appendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over) Introduction / Background Treatment comes after diagnosis Diagnosis is based on
More informationComplications of Diabetes: Screening and Prevention
Complications of Diabetes: Screening and Prevention Dr Steve Cleland Consultant Physician GGH and QEUH Diabetes Staff Education Course June 17 Diabetic Complications Microvascular: Retinopathy Nephropathy
More informationMixing and Matching: Layering Medications as Family Physicians
Mixing and Matching: Layering Medications as Family Physicians Family Medicine Forum Vancouver, B.C. November 9-12, 2016. Jon Davine, CCFP, FRCP(C) McMaster University Objectives Discuss different examples
More informationCELEXA (CITALOPRAM) UTILIZATION AND DOSING MANAGEMENT
BACKGROUND CELEXA (CITALOPRAM) UTILIZATION AND DOSING MANAGEMENT In May 2007, the FDA issued a notice that the agency was updating the black box warning for antidepressants to include warnings about increased
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationGuidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Gene(s)/Level of evidence
Drug Gene(s)/Level of evidence Guidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Haloperidol CYP2D6 ( SLC6A5 ( 2D6: DPWG guidelines Reduce dose by 50% in PMs Aripiprazole
More informationEfficacy and Acceptability of Pharmacological Treatments for Post- Stroke Depression: A Bayesian Network Meta-Analysis
Efficacy and Acceptability of Pharmacological Treatments for Post- Stroke Depression: A Bayesian Network Meta-Analysis Presenter: Miss Deng Tutor: Prof. Liu Ming Department of Neurology West China Hospital
More informationAntidepressants (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors) in children 6-12 years of age with depressive episode/disorder
updated 2012 Antidepressants (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors) in children 6-12 years of age with depressive episode/disorder Q10: Are antidepressants (Tricyclic antidepressants
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationThe earlier BP control the better cardiovascular outcome. Jin Oh Na Cardiovascular center Korea University Medical College
The earlier BP control the better cardiovascular outcome Jin Oh Na Cardiovascular center Korea University Medical College Index Introduction HOPE-3 Trial Sprint Study Summary Each 2 mmhg decrease in SBP
More informationComorbid Conditions and Antipsychotic Use in Patients with Depression
Comorbid Conditions and Antipsychotic Use in Patients with Depression Thomas W. Heinrich, MD Professor of Psychiatry and Family Medicine Director, Division of Consultation-Liaison Psychiatry Medical College
More informationMedication for Anxiety and Depression. PJ Cowen Department of Psychiatry, University of Oxford
Medication for Anxiety and Depression PJ Cowen Department of Psychiatry, University of Oxford Topics Medication for anxiety disorders Medication for first line depression treatment Medication for resistant
More informationGuilt Suicidality. Depression Co-Occurs with Medical Illness The rate of major depression among those with medical illness is significant.
1-800-PSYCH If you are obsessive-compulsive, dial 1 repeatedly If you are paranoid-delusional, dial 2 and wait, your call is being traced If you are schizophrenic, a little voice will tell you what number
More informationAntidepressant use and risk of adverse outcomes in people aged years: cohort study using a primary care database
Coupland et al. BMC Medicine (2018) 16:36 https://doi.org/10.1186/s12916-018-1022-x RESEARCH ARTICLE Open Access Antidepressant use and risk of adverse outcomes in people aged 20 64 years: cohort study
More informationESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future
ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future Rory Collins BHF Professor of Medicine & Epidemiology Clinical Trial Service Unit & Epidemiological Studies
More informationPSYCHIATRY INTAKE FORM
Please complete all information on this form. PSYCHIATRY INTAKE FORM Name Date Date of Birth Primary Care Physician Current Therapist/Counselor What are the problem(s) for which you are seeking help? 1.
More informationObjectives. Objectives. A practice review. 02-Nov-16 MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS
MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS Jon-Paul Khoo What is treatment resistance really? Database review 328 consecutive non-remitted MDD patients referred for private
More informationDaniel Suzuki, MD Adjunct Clinical Associate Professor of Psychiatry, USC Keck School of Medicine Clinical Adjunct Professor/Faculty, Graduate School
Daniel Suzuki, MD Adjunct Clinical Associate Professor of Psychiatry, USC Keck School of Medicine Clinical Adjunct Professor/Faculty, Graduate School of Psychology, Fuller Theological Seminary Medical
More informationPreventive Cardiology Scientific evidence
Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention
More informationGuidance on the use of Antidepressants for the Treatment of Unipolar Depression and Anxiety Spectrum Disorders in adults (Version 3 October 2014)
Guidance on the use of Antidepressants for the Treatment of Unipolar Depression and Anxiety Spectrum Disorders in adults (Version 3 October 2014) Date of Preparation: September 2014 Date for next full
More informationDocument Title Pharmacological Management of Generalised Anxiety Disorder
Document Title Pharmacological Management of Generalised Anxiety Disorder Document Description Document Type Policy Service Application Trust Wide Version 1.1 Policy Reference no. POL 201 Lead Author(s)
More informationManagement of. Depression: Some observations
Management of Psychobiology Research Group Depression: Some observations Hamish McAllister-Williams Reader in Clinical Psychopharmacology, Newcastle University Hon. Consultant Psychiatrist, Regional Affective
More informationFor: NEON Primary Healthcare Providers By: Michelle Romero, DO June 2013
For: NEON Primary Healthcare Providers By: Michelle Romero, DO June 2013 This power point is only a guideline for recommendations in the treatment of psychiatric disorders. This is not comprehensive. Please
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationTHE HEART OF THE MATTER MAYANNA LUND CMH
THE HEART OF THE MATTER MAYANNA LUND CMH CARDIOLOGY ASSESSMENT AND WHEN TO REFER CHEST PAIN - ACUTE History Examination: vital signs are vital ECG Troponin Concerns: MI, unstable angina, PE, aortic dissection
More informationReducing the Anxiety of Pediatric Anxiety Part 2: Treatment
Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment Lisa Lloyd Giles, MD Medical Director, Behavioral Consultation, Crisis, and Community Services Primary Children s Hospital Associate Professor,
More informationSmoking Cessation Pharmacotherapy Guidelines
Smoking Cessation Pharmacotherapy Guidelines INTRODUCTION This guideline is based on public health guidance 10 Smoking Cessation Services issued by the National Institute for Health and Clinical Excellence
More informationALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES MEDICATION FORMULARY
ANTIDEPRESSANTS Serotonin Selective Reuptake Inhibitors citalopram 10, 20, 40 mg, 10 mg/5cc $ 0.40 No escitalopram 10, 20 mg $ 2.60 Yes fluoxetine 10, 20 mg, 20 mg/5 ml $ 0.40 Yes fluvoxamine 25, 50, 100
More informationPractical Guide to Long-Term Pharmacotherapy in Bipolar Disorder: An Updated Synthesis of Current Clinical Guidelines
SECOND-GENERATION ANTIPSYCHOTICS IN BIPOLAR DISORDER Practical Guide to Long-Term Pharmacotherapy in Bipolar Disorder: An Updated Synthesis of Current s Flavio Guzman, MD Editor Psychopharmacology Institute
More informationPSYCHIATRIC MANAGEMENT IN PRIMARY CARE. Dr Fayyaz Khan MBBS, MRCPsych, MSc Consultant Psychiatrist (Locum) Mersey Care NHS Trust
PSYCHIATRIC MANAGEMENT IN PRIMARY CARE Dr Fayyaz Khan MBBS, MRCPsych, MSc Consultant Psychiatrist (Locum) Mersey Care NHS Trust Areas to cover Mood Disorders Anxiety Disorders Miscellaneous Conditions
More informationNHFA CONSENSUS STATEMENT ON DEPRESSION IN PATIENTS WITH CORONARY HEART DISEASE
NHFA CONSENSUS STATEMENT ON DEPRESSION IN PATIENTS WITH CORONARY HEART DISEASE Associate Professor David Colquhoun 19th October 2013 University of Queensland, Wesley & Greenslopes Hospitals, Brisbane,
More informationThey deserve personalized treatment
Your patients are unique They deserve personalized treatment New laboratory service offered by STA 2 R is a panel of genetic tests that gives prescribers answers to the clinical questions below. The test
More informationPsychotropic Medication Use in Dementia
Psychotropic Medication Use in Dementia Marie A DeWitt, MD Diplomate of the American Board of Psychiatry and Neurology, Specialization in Psychiatry & Subspecialization in Geriatric Psychiatry Staff Physician,
More informationDiabetes, Diet and SMI: How can we make a difference?
Diabetes, Diet and SMI: How can we make a difference? Dr. Adrian Heald Consultant in Endocrinology and Diabetes Leighton Hospital, Crewe and Macclesfield Research Fellow, Manchester University Relative
More informationAntidepressant Selection in Primary Care
Antidepressant Selection in Primary Care Rebecca D. Lewis, DO OOA Summer CME Oklahoma City, OK 6 August 2017 Objectives Understand the epidemiology of depression. Recognize factors to help choose antidepressants.
More informationClinical Guideline / Formulary Document Pharmacy Department Medicines Management Services
Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services ANXIETY DISORDERS This guideline covers a range of anxiety disorders, including generalised anxiety disorder, social
More informationReviews/Evaluations. Use of Selective Serotonin Reuptake Inhibitors in Pediatric Patients. Pharmacotherapeutic Options
Reviews/Evaluations Use of Selective Serotonin Reuptake Inhibitors in Pediatric Patients Childhood major depressive disorder (MDD) has become recognized as a serious and common illness affecting between
More informationDepression in Peripheral Artery Disease: An important Predictor of Outcome. Goals. Goals. Marlene Grenon, MD Assistant Professor of Surgery, UCSF
Depression in Peripheral Artery Disease: An important Predictor of Outcome There are no conflicts of interest Marlene Grenon, MD Assistant Professor of Surgery, UCSF UCSF VASCULAR SURGERY SYMPOSIUM SAN
More informationWHAT S NEW. Vilazodone (Viibryd ) Vilazodone - Dosing ANTIDEPRESSANT UPDATE: What s New? The Cardiac Debate The Efficacy Debate?Pharmacogenomics?
ANTIDEPRESSANT UPDATE: What s New? The Cardiac Debate The Efficacy Debate?Pharmacogenomics? Rex S. Lott, Pharm.D., BCPP Professor, ISU College of Pharmacy Mental Health Clinical Pharmacist, Boise VAMC
More informationIlluminating the Black Box: Antidepressants, Youth and Suicide
Illuminating the Black Box: Antidepressants, Youth and Suicide David H. Rubin, M.D. Executive Director, MGH Psychiatry Academy Director, Postgraduate Medical Education Director, Child and Adolescent Psychiatry
More informationAnxiety Disorders.
Anxiety Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationInflammation and and Heart Heart Disease in Women Inflammation and Heart Disease
Inflammation and Heart Disease in Women Inflammation and Heart Disease What is the link between een inflammation and atherosclerotic disease? What is the role of biomarkers in predicting cardiovascular
More informationTreatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center
Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment
More informationMMG004 GUIDELINES FOR THE USE OF HIGH DOSE VENLAFAXINE AND THE COMBINATION OF VENLAFAXINE AND MIRTAZAPINE IN THE TREATMENT OF DEPRESSION
MMG004 GUIDELINES FOR THE USE OF HIGH DOSE VENLAFAXINE AND THE COMBINATION OF VENLAFAXINE AND MIRTAZAPINE IN THE TREATMENT OF DEPRESSION Page 1 of 13 Table of Contents Why we need this Guideline... 3 What
More informationRichard Heidenfelder M.D. Child, Adolescent and Adult Psychiatry 447 9th Ave San Diego, CA
*We are not accepting any New Patients who are currently taking any controlled pain medications *We are *Note: not completion accepting of the any following New Patients paperwork who and Initial are Screening
More information265 medical outpatients evaluated for depression Assessment made by Diagnostic Interview Schedule(DIS) Of 70 patients diagnosed as depressed, only
의학적상태에따른 항우울제치료 이상열원광의대신경정신과 Depression in Physical Illness High prevalence Often unrecognized Often underdiagnosed Often untreated Often inadequately treated 1 Underrecognition of Depression in Medical
More informationManaging Multiple Comorbidities in Bipolar Disorder
Available at CurrentPsychiatry.com/BipolarDepression A SUPPLEMENT TO This promotional, non-cme program is intended only for health care professionals involved in the treatment of adult patients with bipolar
More informationChildren s Hospital Of Wisconsin
Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,
More informationMedications and Children Disorders
Mental Health Comprehensive Services Providing Family Stability and Developing Life Coping Skills Medications and Children Disorders Psychiatric medications can be an effective part of the treatment for
More informationRealities of Depression in Primary Care Setting
Realities of Depression in Primary Care Setting Jaroslava Salman, MD Department of Supportive Care Medicine Division of Psychiatry Click to edit Master Presentation Date August 4 th 2018 Disclosure I have
More informationAntidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry
Antidepressant Medication Strategies We ve Come a Long Way or Have We? Joe Wegmann, PD, LCSW The PharmaTherapist Joe@ThePharmaTherapist.com 504.587.9798 www.pharmatherapist.com Are you receiving our free
More information11. Psychopharmacological Intervention
11. Psychopharmacological Intervention 11.1 Goals of Psychopharmacology The goal of psychopharmacology is to ensure that patients with more severe forms of depression and those who fail to benefit adequately
More informationGuidance on the use of Antidepressants for the Treatment of Unipolar Depression and Anxiety Spectrum Disorders in adults (Version 4.
Guidance on the use of Antidepressants for the Treatment of Unipolar Depression and Anxiety Spectrum Disorders in adults (Version 4.1 December 2018) Date of Preparation: January 2018 (with addition of
More informationNon-A, non-b=hcv; IFN/RBV; DSM-5/Ham-D, OLT; SSRI, P450
James A. Bourgeois, O.D., M.D. Vice Chair Clinical Affairs and Director, CL Service University of California San Francisco Non-A, non-b=hcv; IFN/RBV; DSM-5/Ham-D, OLT; SSRI, P450 Localize! Sequence! 1
More informationPresentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationDepression in Late Life
Depression in Late Life Robert Madan MD FRCPC Geriatric Psychiatrist Key Learnings Robert Madan MD FRCPC Key Learnings By the end of the session, participants will be able to List the symptoms of depression
More informationCurrent Issues in Cardiovascular Risk Management. Les Toop Norman Sharpe June 2014
Current Issues in Cardiovascular Risk Management Les Toop Norman Sharpe June 2014 Risk assessment is just the beginning of a conversation Les Toop Department of General Practice, University of Otago, Christchurch
More informationHeart Failure and COPD: Common Partners, Common Problems. Nat Hawkins Liverpool Heart and Chest Hospital
Heart Failure and COPD: Common Partners, Common Problems Nat Hawkins Liverpool Heart and Chest Hospital Disclosures: No conflicts of interest Common partners, common problems COPD in HF common partners
More informationTreatment Options for Bipolar Disorder Contents
Keeping Your Balance Treatment Options for Bipolar Disorder Contents Medication Treatment for Bipolar Disorder 2 Page Medication Record 5 Psychosocial Treatments for Bipolar Disorder 6 Module Summary 8
More information